BC Innovations | Dec 20, 2019
Distillery Therapeutics

An inhibitor of viral latency for imaging, treating EBV-associated cancers

DISEASE CATEGORY: Cancer INDICATION: Nasopharyngeal cancer; lymphoma A peptide-based compound that inhibits EBNA1, which promotes Epstein-Barr virus latency, could be used to image and treat EBV-associated nasopharyngeal cancer and lymphoma. The compound consists of a...
BC Week In Review | Jul 18, 2016
Company News

Citius Pharmaceuticals sales and marketing update

Citius said it will discontinue FDA-approved Suprenza phentermine orally disintegrating tablets to treat obesity. The company noted the obesity and weight management market has “shifted” and the sympathomimetic amine anorectic “no longer meets our core...
BC Innovations | Dec 17, 2015
Translation in Brief

Old PKIS, new probes

Although there are over 500 kinases in the human genome, under 100 are being actively pursued as therapeutics, because of the lack of chemical probes needed to dissect their function. A public-private partnership headed by...
BC Week In Review | Nov 17, 1997
Company News

Penederm, Allergan deal

Allergan's Allergan-Lok Produtos Pharmaceuticos Ltda. subsidiary (Buenos Aires, Argentina) received an exclusive license to manufacture and market DERM's butenafine topical antifungal cream and its retinoic acid cream acne treatment in Central and South America. DERM...
Items per page:
1 - 4 of 4